Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Morepen Laboratories's average Book Value per Share Growth Rate was 7.80% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 15.60% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 19.30% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 21.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Morepen Laboratories was 32.60% per year. The lowest was -30.80% per year. And the median was -3.60% per year.
Morepen Laboratories (NSE:MOREPENLAB) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Morepen Laboratories 3-Year Book Growth Rate Related Terms
NSE:MOREPENLAB vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's 3-Year Book Growth Rate falls into.
Morepen Laboratories 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 15.60% mean?
Morepen Laboratories (NSE:MOREPENLAB) has a 3-Year Book Growth Rate of 15.60% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Morepen Laboratories and its competitors. According to the industry distribution chart, Morepen Laboratories ranks #174 out of 909 companies in the Drug Manufacturers industry, placing it in the top 19.1%.
Is Morepen Laboratories' 3-Year Book Growth Rate too high?
Morepen Laboratories' current 3-Year Book Growth Rate is 15.60%. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.70. Morepen Laboratories' value of 15.60% is 231.9% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #174 out of 909 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Morepen Laboratories has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #174 out of 909 companies for 3-Year Book Growth Rate. This places Morepen Laboratories in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.70. Morepen Laboratories' value of 15.60% is 231.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.70, based on 909 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current 3-Year Book Growth Rate of 15.60% is 231.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current 3-Year Book Growth Rate is 15.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹54.30, compared to a current price of ₹96.01 — trading 76.8% above its estimated fair value. The current 3-Year Book Growth Rate is 15.60% and 231.9% above the Drug Manufacturers industry median of 4.70. Morepen Laboratories' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current 3-Year Book Growth Rate is 15.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹96.01 is trading 76.8% above its estimated GF Value™ of ₹54.30.
GuruFocus considers Morepen Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
3-Year Book Growth Rate: 15.60%
GF Value™: ₹54.30 vs. price of ₹96.01 (76.8% above fair value)
Industry Position: 231.9% above the Drug Manufacturers median (#174 of 909)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
66GF Score
Get the complete analysis for NSE:MOREPENLAB
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
